Sensidose Overview
- Founded
-
1998
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
SENSI
- Share Price
-
$0.34
- (As of Wednesday Closing)
Sensidose General Information
Description
Sensidose AB is a pharmaceutical company that has developed a system for individualized dosing of tablets, a medical treatment using a dosing device pre-programmed for the patient. The system consists of tablets, containing low doses in each individual tablet. Its product comprises MYFID and FLEXILEV. The micro- tablets are retrieved using an automated dispenser. The dispenser has an inbuilt alarm, delivers doses at the programmed time point, and registers all doses delivered as well as disease symptoms with the help of easy-to-use scales.
Contact Information
Primary Industry
Other Devices and Supplies
Stock Exchange
SAT
Primary Office
- Vetenskapsvägen 10
- 191 38 Sollentuna
- Sweden
+46 010-707 00 00
Sensidose Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.34 | $0.34 | $0.30 - $0.45 | $4.11M | 12M | 9.4K | -$0.04 |
Sensidose Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| Revenue | 811 | 811 | 755 | 309 |
| EBITDA | (292) | (292) | (527) | (818) |
| Net Income | (470) | (470) | (859) | |
| Total Assets | 1,735 | 1,735 | 1,768 | |
| Total Debt | 432 | 432 | 547 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Sensidose Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sensidose Patents
Sensidose Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3065105-A1 | Systems for evaluating dosage parameters | Pending | 31-May-2017 | 000000000 | |
| GB-201708624-D0 | System for evaluating dosage parameters | Ceased | 31-May-2017 | 000000000 | |
| EP-3635729-A1 | Systems for evaluating dosage parameters | Pending | 31-May-2017 | 000000000 | |
| US-20200168310-A1 | Systems for evaluating dosage parameters | Pending | 31-May-2017 | 000000000 | |
| US-11040013-B2 | Compacted powder | Active | 12-Nov-2015 | A61K9/2072 | 0 |
Sensidose Executive Team (7)
Sensidose Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bo-Ragnar Tolf Ph.D | Self | Board Member | 000 0000 |
| Ingemar Kihlström | Sensidose | Co-Chairman | 000 0000 |
| Jack Spira Ph.D | Self | Chief Executive Officer & Board Member | 000 0000 |
| Lasse Tenerz | Self | Board Member | 000 0000 |
| Per Nilsson | Sensidose | Co-Chairman | 000 0000 |
Sensidose Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
